Forest files suit over Bystolic patent; generic Lexapro launched in USA

15 March 2012

US drugmaker Forest Laboratories (NYSE: FRX) and Janssen Pharmaceutica, a unit of health care giant Johnson & Johnson (NYSE: JNJ), have jointly filed a law suit in the US District Court for the District of Delaware against several companies for infringement of the US patent relating to their antihypertensive Bystolic (nebivol), which they say expires in December 2021, including patent term extension.

The defendants named in the law suit include Amerigen Pharmaceuticals, Glenmark Generics, Hetero USA, Torrent Pharmaceuticals, Watson Laboratories and related companies and subsidiaries. Forest and Janssen (which licensed Bystolic to Forest) also filed a law suit in the US District Court for the Northern District of Illinois against Alkem Laboratories and Indchemie Health Specialties for infringement of the patent.

Watson confirms ANDA filing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK